{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:32:00Z","timestamp":1778632320366,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20181BAB205016"],"award-info":[{"award-number":["20181BAB205016"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970583"],"award-info":[{"award-number":["81970583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This retrospective study aimed to explore the relative efficacy and safety of different tacrolimus (TAC) concentrations in the treatment of patients with idiopathic membranous nephropathy (IMN). A total of 260 IMN patients with nephrotic syndrome (NS) were recruited. Among these, 125 patients had TAC concentrations no greater than 5\u00a0ng\/ml (C<jats:sub>TAC<\/jats:sub>\u2009\u2264\u20095\u00a0ng\/ml), and 135 patients had TAC concentrations greater than 5\u00a0ng\/ml (C<jats:sub>TAC<\/jats:sub>\u2009&gt;\u20095\u00a0ng\/ml). The primary outcomes included complete remission (CR) rates and overall (OR) response rates. The secondary outcomes included 24-h urinary protein (24-h UP), serum albumin and serum creatinine, and adverse events (AEs). During the 12-month follow-up, the overall response rates were significantly different between the C<jats:sub>TAC<\/jats:sub>\u2009\u2264\u20095\u00a0ng\/ml group and the C<jats:sub>TAC<\/jats:sub>\u2009&gt;\u20095\u00a0ng\/ml group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). However, there was no significant difference in the CR at 12\u00a0months between the two groups (chi-square, 62% vs 63%, <jats:italic>P<\/jats:italic>\u2009=\u20090.852). Compared with the C<jats:sub>TAC<\/jats:sub>\u2009\u2264\u20095\u00a0ng\/ml group, the C<jats:sub>TAC<\/jats:sub>\u2009&gt;\u20095\u00a0ng\/ml group had improved levels of 24\u00a0h UP (<jats:italic>P<\/jats:italic>\u2009=\u20090.017) and serum albumin (<jats:italic>P<\/jats:italic>\u2009=\u20090.010). Moreover, the incidences of acute reversible nephrotoxicity (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), hepatotoxicity (<jats:italic>P<\/jats:italic>\u2009=\u20090.036), new-onset diabetes mellitus (<jats:italic>P<\/jats:italic>\u2009=\u20090.036), and glucose intolerance (<jats:italic>P<\/jats:italic>\u2009=\u20090.005) were lower in the C<jats:sub>TAC<\/jats:sub>\u2009\u2264\u20095\u00a0ng\/ml group than in the C<jats:sub>TAC<\/jats:sub>\u2009&gt;\u20095\u00a0ng\/ml group. The C<jats:sub>TAC<\/jats:sub>\u2009&gt;\u20095\u00a0ng\/ml group was improved relative to the C<jats:sub>TAC<\/jats:sub>\u2009\u2264\u20095\u00a0ng\/ml group in terms of a PR and CR at 6\u00a0months, but there was no difference in the CR between the two groups at 12\u00a0months.<\/jats:p>","DOI":"10.1038\/s41598-021-92678-y","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T10:02:56Z","timestamp":1624528976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"92678_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","volume":"56","author":"RJ Glassock","year":"2010","unstructured":"Glassock, R. J. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am. J. Kidney Dis. 56, 157\u2013167 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"92678_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000348638","volume":"181","author":"X Pan","year":"2013","unstructured":"Pan, X. et al. Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China. Contrib. Nephrol. 181, 22\u201330 (2013).","journal-title":"Contrib. Nephrol."},{"key":"92678_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","volume":"23","author":"R Glassock","year":"2003","unstructured":"Glassock, R. Diagnosis and natural course of membranous nephropathy. Semin. Nephrol. 23, 324\u2013332 (2003).","journal-title":"Semin. Nephrol."},{"key":"92678_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco, N. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697\u2013704 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"92678_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati, A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 329, 85\u201389 (1993).","journal-title":"N. Engl. J. Med."},{"key":"92678_CR6","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1046\/j.1523-1755.1999.07007.x","volume":"70","author":"N Muirhead","year":"1999","unstructured":"Muirhead, N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int. Suppl. 70, S47-55 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"92678_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"TH Tran","year":"2007","unstructured":"Tran, T. H. et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924\u2013930 (2007).","journal-title":"Kidney Int."},{"key":"92678_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"92678_CR9","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1517\/14656566.2010.494599","volume":"11","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli, C. & Passerini, P. Management of idiopathic membranous nephropathy. Expert Opin. Pharmacother. 11, 2163\u20132175 (2010).","journal-title":"Expert Opin. Pharmacother."},{"key":"92678_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1523-1755.1998.00017.x","volume":"54","author":"SB Vercauteren","year":"1998","unstructured":"Vercauteren, S. B. et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int. 54, 536\u2013545 (1998).","journal-title":"Kidney Int."},{"key":"92678_CR11","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053\u20132060 (2002).","journal-title":"N. Engl. J. Med."},{"key":"92678_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1681\/ASN.2007121292","volume":"19","author":"MP Winn","year":"2008","unstructured":"Winn, M. P. 2007 Young investigator award: TRP\u2019inginto a new era for glomerular disease. J. Am. Soc. Nephrol. 19, 1071\u20131075 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"92678_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.ajpath.2011.06.033","volume":"179","author":"T Nijenhuis","year":"2011","unstructured":"Nijenhuis, T. et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am. J. Pathol. 179, 1719\u20131732 (2011).","journal-title":"Am. J. Pathol."},{"key":"92678_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen, M. et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am. J. Med. Sci. 339, 233\u2013238 (2010).","journal-title":"Am. J. Med. Sci."},{"key":"92678_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.transproceed.2005.12.083","volume":"38","author":"K Falkiewicz","year":"2006","unstructured":"Falkiewicz, K. et al. Renal function and tubular phosphate handling in long-term cyclosporineand tacrolimus-based immunosuppression in Kidney transplantation. Transplant. Proc. 38, 119\u2013122 (2006).","journal-title":"Transplant. Proc."},{"key":"92678_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(98)07493-5","volume":"353","author":"MD Denton","year":"1999","unstructured":"Denton, M. D., Magee, C. C. & Sayegh, M. H. Immunosuppressive strategies in transplantation. Lancet 353, 1083\u20131091 (1999).","journal-title":"Lancet"},{"key":"92678_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5414\/CNP65393","volume":"65","author":"TH Westhoff","year":"2006","unstructured":"Westhoff, T. H. et al. Tacrolimus in steroidresistant and steroid-dependent nephrotic syndrome. Clin. Nephrol. 65, 393\u2013400 (2006).","journal-title":"Clin. Nephrol."},{"key":"92678_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/ndt\/17.4.655","volume":"17","author":"A Segarra","year":"2002","unstructured":"Segarra, A. et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or-dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. 17, 655\u2013662 (2002).","journal-title":"Nephrol. Dial. Transplant."},{"key":"92678_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","volume":"19","author":"K Loeffler","year":"2004","unstructured":"Loeffler, K., Gowrishankar, M. & Yiu, V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr. Nephrol. 19, 281\u2013287 (2004).","journal-title":"Pediatr. Nephrol."},{"key":"92678_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00467-004-1778-4","volume":"20","author":"T Ulinski","year":"2005","unstructured":"Ulinski, T. et al. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr. Nephrol. 20, 482\u2013485 (2005).","journal-title":"Pediatr. Nephrol."},{"key":"92678_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00467-005-1877-x","volume":"20","author":"S Mendizabal","year":"2005","unstructured":"Mendizabal, S. et al. Mycophenolate mofetil in steroid\/cyclosporine-dependent\/resistant nephrotic syndrome. Pediatr. Nephrol. 20, 914\u2013919 (2005).","journal-title":"Pediatr. Nephrol."},{"key":"92678_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.healun.2005.11.452","volume":"25","author":"JA Kobashigawa","year":"2006","unstructured":"Kobashigawa, J. A. et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J. Heart Lung Transpl. 25, 434\u2013439 (2006).","journal-title":"J. Heart Lung Transpl."},{"key":"92678_CR23","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1056\/NEJMoa020009","volume":"349","author":"BJ Nankivell","year":"2003","unstructured":"Nankivell, B. J. et al. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349, 2326\u20132333 (2003).","journal-title":"N. Engl. J. Med."},{"key":"92678_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2009.02.018","volume":"54","author":"X Li","year":"2009","unstructured":"Li, X. et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am. J. Kidney Dis. 54, 51\u201358 (2009).","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"92678_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tcb.2010.09.011PMID:21115349;PubMedCentralPMCID:PMC3244350","volume":"21","author":"H Li","year":"2011","unstructured":"Li, H., Rao, A. & Hogan, P. G. Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol. 21(2), 91\u2013103. https:\/\/doi.org\/10.1016\/j.tcb.2010.09.011PMID:21115349;PubMedCentralPMCID:PMC3244350 (2011).","journal-title":"Trends Cell Biol."},{"issue":"10","key":"92678_CR26","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nm.2497PMID:21963515","volume":"17","author":"EJ Hoom","year":"2011","unstructured":"Hoom, E. J. et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporterto cause hypertension. Nat. Med. 17(10), 1304\u20131309. https:\/\/doi.org\/10.1038\/nm.2497PMID:21963515 (2011).","journal-title":"Nat. Med."},{"issue":"4","key":"92678_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1365-2125.2011.04118.x","volume":"73","author":"LA Ozbay","year":"2012","unstructured":"Ozbay, L. A. et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br. J. Clin. Pharmacol. 73(4), 536\u2013545. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04118.x (2012).","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92678-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:37:49Z","timestamp":1670063869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92678-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92678"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92678-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13274"}}